Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapse-prevention study of vortioxetine in paediatric major depressive disorder
2010-020493-42Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoint: Time to relapse. Started Mar 2021; status: terminated.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-020493-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020493-42.